Amarin Announces FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed

Amarin Announces FDA Advisory Committee Outcome for the Use of Vascepa in the
Treatment of High Triglycerides With Mixed Dyslipidemia

Conference Call Set for 7:00 p.m. ET Today

BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that the U.S. Food and Drug Administration (FDA)
Endocrinologic and Metabolic Drugs Advisory Committee has voted 9 to 2 against
approval of Vascepa^® (icosapent ethyl) capsules for use as an adjunct to diet
and exercise and in combination with a statin in the treatment of adult
patients with high triglycerides (TG 200-499 mg/dL) with mixed dyslipidemia
and coronary heart disease (CHD) or a CHD risk equivalent (the ANCHOR
indication) based on the information presented at the committee meeting today.

The FDA is scheduled to make its decision on whether to approve the ANCHOR
Supplemental New Drug Application (sNDA) on the December 20, 2013 Prescription
Drug User Fee Act (PDUFA) goal date for the application.

Vascepa is currently approved by the FDA for use as an adjunct to diet to
reduce triglyceride levels in adult patients with severe ( ≥ 500 mg/dL)
hypertriglyceridemia.

Conference call today

As planned, members of the Amarin management team will host a webcast and
conference call to discuss the Advisory Committee recommendation today at 7:00
p.m. ET.

The conference call can be heard live via the investor relations section of
the company's website at www.amarincorp.com, or via telephone by dialing
877-407-8033 within the United States or 201-689-8033 from outside the United
States. A replay of the call will be made available for a period of two weeks
following the conference call. To hear a replay of the call, dial 877-660-6853
(inside the United States) or 201-612-7415 (outside the United States). A
replay of the call will also be available through the company's website
shortly after the call. For both dial-in numbers please use conference ID
100205.

About Vascepa^®(icosapent ethyl) capsules

Vascepa^®(icosapent ethyl) capsules, known in scientific literature as
AMR101, is a patented, pure-EPAomega-3 prescription product in a 1 gram
capsule.

Indications and Usage

  *Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce
    triglyceride (TG) levels in adult patients with severe ( ≥ 500 mg/dL)
    hypertriglyceridemia.
  *The effect of Vascepa on the risk for pancreatitis and cardiovascular
    mortality and morbidity in patients with severe hypertriglyceridemia has
    not been determined.

Important Safety Information for Vascepa

  *Vascepa is contraindicated in patients with known hypersensitivity (e.g.,
    anaphylactic reaction) to Vascepa or any of its components and should be
    used with caution in patients with known hypersensitivity to fish and/or
    shellfish.
  *The most common reported adverse reaction (incidence> 2% and greater than
    placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo).

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND ATWWW.VASCEPA.COM

Vascepa is under various stages of development for potential use in other
indications that have not been approved by the FDA.Nothing in this press
release should be construed as marketing the use of Vascepa in any indication
that has not been approved by the FDA.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (www.amarincorp.com), our investor
relations website (http://www.amarincorp.com/investor-splash.html), including
but not limited to investor presentations and investor FAQs,Securities and
Exchange Commissionfilings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.